



May 26, 2022

Notice Regarding Offer of Refunds to 340B Covered Entities

e5 Pharma, LLC (“e5 Pharma”) has recently recalculated the 340B Ceiling Prices for the NDCs listed below for the time period 1st calendar quarter 2021 (January 1, 2021 – March 31, 2021). As a result of the recalculation, a refund is or may be owed to 340B Covered Entities that purchased the NDCs below during the period of January 1, 2021 – March 31, 2021.

Please see the following NDCs:

Product Description	NDC
PHENOBARBITAL TABLET 16.2MG 100CT	13517-0100-01
PHENOBARBITAL TABLET 16.2MG 1000CT	13517-0100-10
PHENOBARBITAL TABLET 32.4MG 100CT	13517-0110-01
PHENOBARBITAL TABLET 32.4MG 1000CT	13517-0110-10
PHENOBARBITAL TABLET 64.8MG 100CT	13517-0112-01
PHENOBARBITAL TABLET 64.8MG 1000CT	13517-0112-10

Based upon the recalculation for the products listed above, e5 Pharma intends to refund affected 340B Covered Entities. E5 Pharma will submit payment to the affected 340B covered entity by check and will include details of the payment. The payment package will be sent to the 340B Covered Entity.

E5 Pharma invites interested affected parties to contact the company via email at 340B@e5pharma.com, with reference to the applicable NDCs.

E5 Pharma has asked the Health Resources Services Administration (“HRSA”) to post this notice on the HRSA public website to ensure transparency to all 340B Covered Entities regarding the 340B Ceiling Price revision and to offer a refund to affected Covered Entities. Please direct all inquiries to 561-288-4885.

If there are any questions or concerns, please feel free to reach out to our HRSA contact – Tom Larkin at tom@e5pharma.com. Thank you for your partnership.

Sincerely,

Tom Larkin – e5 Pharma President

225 NE Mizner Blvd. Suite 770
Boca Raton, FL 33432
561-288-4885

